€13.4m at the end of December 2023. These mainly comprise depreciation of assets linked to the Drontal® and Profender® products. Group EBIT rose by €4.5 million to €76.1 million (14.1% of ...

These mainly comprise depreciation of assets linked to the Drontal® and Profender® products. Group EBIT rose by €4.5 million to €76.1 million (14.1% of sales) from €71.6 million in 2023.

Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the ...

After hours: March 26 at 5:55:05 p.m. EDT Loading Chart for ELAN ...